242 related articles for article (PubMed ID: 17343760)
21. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
22. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.
Loomis SJ; Chen Y; Sacks DB; Christenson ES; Christenson RH; Rebholz CM; Selvin E
Clin Chem; 2017 May; 63(5):980-989. PubMed ID: 28280052
[TBL] [Abstract][Full Text] [Related]
23. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
[TBL] [Abstract][Full Text] [Related]
24. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes.
Miranda ER; Somal VS; Mey JT; Blackburn BK; Wang E; Farabi S; Karstoft K; Fealy CE; Kashyap S; Kirwan JP; Quinn L; Solomon TPJ; Haus JM
Am J Physiol Endocrinol Metab; 2017 Dec; 313(6):E631-E640. PubMed ID: 28811295
[TBL] [Abstract][Full Text] [Related]
25. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
Colhoun HM; Betteridge DJ; Durrington P; Hitman G; Neil A; Livingstone S; Charlton-Menys V; Bao W; Demicco DA; Preston GM; Deshmukh H; Tan K; Fuller JH
Diabetes; 2011 Sep; 60(9):2379-85. PubMed ID: 21771973
[TBL] [Abstract][Full Text] [Related]
26. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
[TBL] [Abstract][Full Text] [Related]
27. Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes.
Di Pino A; Urbano F; Zagami RM; Filippello A; Di Mauro S; Piro S; Purrello F; Rabuazzo AM
J Clin Endocrinol Metab; 2016 Apr; 101(4):1701-9. PubMed ID: 26885882
[TBL] [Abstract][Full Text] [Related]
28. RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus.
Peng WH; Lu L; Wang LJ; Yan XX; Chen QJ; Zhang Q; Zhang RY; Shen WF
Arch Med Res; 2009 Jul; 40(5):393-8. PubMed ID: 19766904
[TBL] [Abstract][Full Text] [Related]
29. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).
Leonardis D; Basta G; Mallamaci F; Cutrupi S; Pizzini P; Tripepi R; Tripepi G; De Caterina R; Zoccali C
Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):748-55. PubMed ID: 21470837
[TBL] [Abstract][Full Text] [Related]
30. Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation.
Shen Y; Pu LJ; Lu L; Zhang Q; Zhang RY; Shen WF
Can J Cardiol; 2012; 28(6):737-43. PubMed ID: 23073352
[TBL] [Abstract][Full Text] [Related]
31. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood.
Giannini C; D'Adamo E; de Giorgis T; Chiavaroli V; Verrotti A; Chiarelli F; Mohn A
Pediatr Nephrol; 2012 Feb; 27(2):269-75. PubMed ID: 21870072
[TBL] [Abstract][Full Text] [Related]
32. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.
Norata GD; Garlaschelli K; Grigore L; Tibolla G; Raselli S; Redaelli L; Buccianti G; Catapano AL
Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):129-34. PubMed ID: 18595673
[TBL] [Abstract][Full Text] [Related]
33. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients.
Yan XX; Lu L; Peng WH; Wang LJ; Zhang Q; Zhang RY; Chen QJ; Shen WF
Atherosclerosis; 2009 Aug; 205(2):544-8. PubMed ID: 19150066
[TBL] [Abstract][Full Text] [Related]
34. Association Between Soluble Receptor for Advanced Glycation End Product and Endogenous Secretory Soluble Receptor for Advanced Glycation End Product Levels and Carotid Atherosclerosis in Diabetes: A Systematic Review and Meta-Analysis.
Wang X; Wang Q; Wei D; Chang X
Can J Diabetes; 2021 Oct; 45(7):634-640. PubMed ID: 33773934
[TBL] [Abstract][Full Text] [Related]
35. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes.
Tam HL; Shiu SW; Wong Y; Chow WS; Betteridge DJ; Tan KC
Atherosclerosis; 2010 Mar; 209(1):173-7. PubMed ID: 19733353
[TBL] [Abstract][Full Text] [Related]
36. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus.
Skrha J; Kalousová M; Svarcová J; Muravská A; Kvasnička J; Landová L; Zima T; Skrha J
Exp Clin Endocrinol Diabetes; 2012 May; 120(5):277-81. PubMed ID: 22549347
[TBL] [Abstract][Full Text] [Related]
37. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
[TBL] [Abstract][Full Text] [Related]
38. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.
Thomas MC; Söderlund J; Lehto M; Mäkinen VP; Moran JL; Cooper ME; Forsblom C; Groop PH;
Diabetologia; 2011 Oct; 54(10):2669-77. PubMed ID: 21607631
[TBL] [Abstract][Full Text] [Related]
39. Development of an ELISA for esRAGE and its application to type 1 diabetic patients.
Sakurai S; Yamamoto Y; Tamei H; Matsuki H; Obata K; Hui L; Miura J; Osawa M; Uchigata Y; Iwamoto Y; Watanabe T; Yonekura H; Yamamoto H
Diabetes Res Clin Pract; 2006 Aug; 73(2):158-65. PubMed ID: 16488505
[TBL] [Abstract][Full Text] [Related]
40. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria.
Krzyzanowska K; Mittermayer F; Shnawa N; Hofer M; Schnabler J; Etmüller Y; Kapiotis S; Wolzt M; Schernthaner G
Diabet Med; 2007 Jan; 24(1):81-6. PubMed ID: 17227328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
